Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $219.7 million.

  • Neurocrine Biosciences' Other Non-Current Liabilities rose 3219.01% to $219.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $219.7 million, marking a year-over-year increase of 3219.01%. This contributed to the annual value of $219.7 million for FY2025, which is 3219.01% up from last year.
  • Neurocrine Biosciences' Other Non-Current Liabilities amounted to $219.7 million in Q4 2025, which was up 3219.01% from $195.7 million recorded in Q3 2025.
  • Neurocrine Biosciences' Other Non-Current Liabilities' 5-year high stood at $219.7 million during Q4 2025, with a 5-year trough of $8.3 million in Q3 2021.
  • For the 4-year period, Neurocrine Biosciences' Other Non-Current Liabilities averaged around $116.6 million, with its median value being $135.0 million (2024).
  • Per our database at Business Quant, Neurocrine Biosciences' Other Non-Current Liabilities plummeted by 138.89% in 2021 and then surged by 22978.21% in 2024.
  • Over the past 4 years, Neurocrine Biosciences' Other Non-Current Liabilities (Quarter) stood at $8.3 million in 2021, then soared by 1180.72% to $106.3 million in 2023, then surged by 56.35% to $166.2 million in 2024, then skyrocketed by 32.19% to $219.7 million in 2025.
  • Its Other Non-Current Liabilities stands at $219.7 million for Q4 2025, versus $195.7 million for Q3 2025 and $210.1 million for Q2 2025.